Is Obinutuzumab included in medical insurance?

Obinutuzumab has entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Administration after being launched in China, but it is only reimbursed for patients who meet the indications, including combination with chemotherapy for initial treatment of adult patients with stage 11, stage or IV follicular lymphoma with huge masses. Patients who achieve at least partial response are subsequently treated with obinutuzumab for maintenance treatment.

Otuzumab is a monoclonal antibody. Monoclonal antibodies are made in the laboratory to attach to specific types of cancer cells. Antibodies"summon" the immune system to attack the cells to which they are attached, causing the immune system to kill the cells. These antibodies can work in different ways, including stimulating the immune system to kill cells, preventing cell growth or other functions needed for cell growth. Otuzumabtargets a protein calledCD20, which is found on the surface of normal and cancerous B cells, which are part of the immune system. More than 90% of CLL cases affect B cells, making them an excellent target for treatment. Once the drug attaches to CD20-expressing B cells, it summons the body's immune system to attack and destroy those cells.

Otuzumab original drug specification1000mg (40ml)*1 bottle sold in China may cost around 9,000 yuan, and is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.